Vanda Pharmaceuticals Inc. (VNDA) Guidance & Earnings Results
On 2026-08-05 Vanda Pharmaceuticals Inc. reaffirmed guidance: "Full-year 2026 total revenue guidance of $240-$290…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VNDAVanda Pharmaceuticals Inc.Follow VNDA — free
—
Price chart with a free account
- Market cap
- 242.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Reaffirmed | Full-year 2026 total revenue guidance of $240-$290 million · full year |
| 6 May 26 | Raised | Revenue guidance raised to $240-$290M from prior range · full year |
| 11 Feb 26 | Raised | FY2026 total revenue guidance $230-260M · full year |
Vanda Pharmaceuticals Inc. — questions
- What guidance did Vanda Pharmaceuticals Inc. give?
- On 2026-08-05: "Full-year 2026 total revenue guidance of $240-$290 million"
- When does Vanda Pharmaceuticals Inc. report earnings?
- Vanda Pharmaceuticals Inc.'s next earnings report is expected on 2026-10-28.
Every figure on this page comes from Vanda Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.